EUVIMEDEUVIMED entdecken
Crossref

The EMERALD-3 Trial: STRIDE with or without Lenvatinib plus TACE for Embolization-eligible Hepatocellular Carcinoma

Ridvan A Demirci iD, Gustavo H Andrade

Radiology: Imaging Cancer · 01.11.2026 · 8 (6)

DOI: 10.1148/rycan.269025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiology: Imaging Cancer, erschienen am 01.11.2026. Verfasst von Ridvan A Demirci und 1 weiteren Autor:innen. Die Arbeit nennt 1 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

ORCID-Profile: Ridvan A Demirci

Zitieren

APA

Demirci, R. A., & Andrade, G. H. (2026). The EMERALD-3 Trial: STRIDE with or without Lenvatinib plus TACE for Embolization-eligible Hepatocellular Carcinoma. Radiology: Imaging Cancer, 8(6). https://doi.org/10.1148/rycan.269025

Vancouver

Demirci RA, Andrade GH. The EMERALD-3 Trial: STRIDE with or without Lenvatinib plus TACE for Embolization-eligible Hepatocellular Carcinoma. Radiology: Imaging Cancer. 2026;8(6). doi:10.1148/rycan.269025

BibTeX
@article{Demirci2026,
  author = {Demirci, Ridvan A and Andrade, Gustavo H},
  title = {The EMERALD-3 Trial: STRIDE with or without Lenvatinib plus TACE for Embolization-eligible Hepatocellular Carcinoma},
  journal = {Radiology: Imaging Cancer},
  year = {2026},
  volume = {8},
  number = {6},
  doi = {10.1148/rycan.269025}
}
Kostenlos starten →